Ukrainian scientists have developed a new method for the treatment of keratites, using the placental amniotic membrane

In recent years, the placenta has become an increasingly attractive object of biobanking. Biobanks worldwide, besides storage of the umbilical cord blood stem cells and umbilical cord, are also increasingly offering storage of the placenta. This is due to the great medical value of this biomaterial, whose full potential has not yet been fully elucidated.

In Ukraine, significant progress has been made in the placenta research by scientists of the Institute of Cell Therapy, a member of the International Placenta Stem Cells Society (IPLASS) and the International Federation of Placenta Associations  (IFPA). The Institute of Cell Therapy is also a co-author of the international project COST action CA17116  on the study of placenta stem cells, funded by the European Union.

One of the most important achievements of the Institute of Cell Therapy in the field of cryopreservation of the placenta has been developed in conjunction with the Filatov Institute of Eye Diseases and  Tissue Therapy of NAMSU, a method of treatment of keratitis using an amniotic membrane of the placenta. Both institutions, the Institute of Cell Therapy and the the Filatov Institute of Eye Diseases and  Tissue Therapy of NAMSU, are members of the Association of Cryobanks.

 

Keratitis is an inflammation of the cornea of ​​the eye, which, in the case of absence of proper treatment, can lead to blemishes, loss of vision and deterioration in the quality of life of the patient.

Under the auspices of the Coordination Center for the Transplantation of Organs, Tissues and Cells of the Ministry of Health of Ukraine, the Institute of Cell Therapy on the basis of the IFilatov Institute of Eye Diseases and  Tissue Therapy of NAMSU conducted an approbation of this innovative method of treatment of keratites of infectious and neurotrophic etiology in the framework of clinical trial.

As a result of several years of research, the good engraftment of the transplanted amniotic membrane of the human placenta was shown as well as its high elasticity and strength. No complications or allergic reactions to the graft were observed.

In 100% of patients with neurotrophic, herpetic and bacterial keratitis, high efficacy of the transplanted drug of the placenta amniotic membrane, cryopreserved in the Cryobank of the Institute of Cell Therapy, was demonstrated. Significant increase of vision in patients after transplantation of the placenta amniotic membrane was also noted.

The Association of Cryobanks supports the registration of the surgical treatment of keratitis using the placenta amniotic membrane, cryopreserved according to the Institute of Cell Therapy Cryobank method in order to make this effective innovative treatment available to a wide range of patients.

No Comments Yet.

Leave a comment

You must be logged in to post a comment.